Granules India to acquire Auctus Pharma and opens new R&D facility

On November 4, 2013, pharmaceutical manufacturer Granules India announced that it has entered into an agreement with Auctus Pharma, an API (Active Pharmaceutical Ingredients) manufacturer, for its acquisition for Rs 120 crore.

biospec-krishna-prasad-md-granules-india

Mr Krishna Prasad, managing director, Granules India

"The acquisition of Auctus fits into our strategy of being a fully integrated manufacturer while diversifying our product portfolio by adding high-value products with significant market demand. We will be a market leader by implementing our operational excellence philosophy while leveraging Auctus' regulatory approvals. In order to accelerate growth with a sustainable development engine, we have established a new R&D facility to enable finished dosage filings for our new APIs," said Mr Krishna Prasad, managing director, Granules India.

Currently, Auctus has two manufacturing facilities, an API facility in Vishakhapatnam and an intermediate facility in Hyderabad.

The API facility has approvals from regulatory agencies including the US FDA, EDQM and KFDA.

Auctus' APIs therapeutic categories includes Antihistaminic, Antihypertensive, Antithrombotic and Anticonvulsant.

Granules also announced the opening of its 10,000 sq. foot R&D facility in Hyderabad.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X